Genadur

The First and Only FDA Approved Product to Relieve Symptoms and Signs of Onychodystrophy

Genadur® is proven to:

  • Strengthen fragile nails
  • Improve nail appearance
  • Reduce nail splitting
  • Avoid damage caused by nail solvents

Formulated to address fragile, brittle or split nails caused by:

  • Onychomycosis
  • Environmental factors
  • Psoriasis
  • Chemical exposure to detergents, solvents, and cleansers

Unique hydrosoluble nail lacquer formulation containing hydroxypropyl-chitosan (HPCH), equisetum arvense and methyl sulfonyl methane (MSM)

HPCH

  • Penetrates intercellular spaces and nail surface ridges
    • Provides physical support
    • Creates a barrier against external agents
      • Accelerates nail growth
      • Smoothes the nail surface

Equisetum arvense

  • Provides essential minerals which integrate with the keratin of the nail
  • Contains a high amount of organic silica
    • Helps maintain strong nails
    • Collagen-forming agent support cracked, split or brittle nails

MSM

  • Natural sulfar donor essential for keratin formation 
    • Disulfide bonds stabilize keratin filaments and help harden the nail plate
  • In 77% of patients with brittle nails, sulfar content was decreased 3 

Clinical Results

Lamellar Splitting1

Genadur® showed 85% reduction in patients reporting lamellar splitting of treated nails, while no significant change was observed in untreated controls

  • Significant reduction of severity in nail splitting 
  • Longitudinal ridges were significantly reduced after only 14 days, despite the harmful effects of solvents

Nail Fragility1

Genadur® showed 90% of cases with 1 grade improvement in nail fragility after 14 days

  • Longitudinal grooves were significantly reduced (28%) after 14 days
  • Studies showed a significant decrease of lamellar splitting compared to baseline

Psoriatic Onychodystrophy2

Genadur® showed a statistically significant improvement in patients with mild-to-moderate nail psoriasis

  • Genadur® showed a 72% reduction in pitting, 66% for leukonychia and 63% for onyocholysis
  • Clinical affects started to be evident at 12 weeks for 50% of patients

IMPORTANT SAFETY INFORMATION

Genadur® is for external use only.  Eye contact should be avoided.  It is contraindicated in patients with known hypersensitivity to any of the components. Please see full prescribing information.
RX - Prescription Medical Device: Federal Law restricts this device to sale by or on the order of a physician.

1Journal of Plastic Dermatology 2006: Vol. 2, n. 1 January-April. Equisetum averense in a New Transungual Technology Improves Nail Structure and Appearance. Sparavigna A, Setaro M, Genet M, Frisenda L.
2Journal of the Euopean Academy of Dermatology and Venereology2009: Vol. 23, n. 7 July. Improvement of Psoriatic Onychodystrophy by a Water-soluble Nail Lacquer. Cantoresi, P, Sorgi P, Arcese A, Bidoli A, Bruni F, Canevale C, Calvieri S.
3Journal of American Academy of Dermatology 2005: Vol. 53, October, Brittle Nail System: A Pathogenesis-based Approach with a Proposed Grading System, van de Kerkhof P, Pasch M, Scher R, Kerscher M, Gieler U, Haneke E, Fleckman, P.

Medimetriks Pharmaceuticals, Inc.
383 Route 46 West
Fairfield, NJ 07004-2402 USA
 
[ Back ]